Summary of Key Points
Global pharmaceutical giants are facing a significant growth gap due to the "patent cliff," urgently seeking high-quality new drug assets to fill this void. Chinese innovative drugs have shifted from being valued solely for their market size to becoming highly sought-after by multinational companies due to their robust clinical data and advanced technologies (such as ADCs and bispecific antibodies). The amount of external licensing transactions has surged, reaching $99.7 billion in the first half of 2026—nearly 73% of the total for 2025. However, most of these transactions are still based on a "one-way sale" model, where Chinese companies receive only short-term upfront payments and milestone fees, with limited long-term global revenue and capability building. Experts suggest that Chinese firms should strive for co-development rights, enhance their internal teams' capabilities, and create competition among buyers to move beyond short-term profit gains and towards shared global value, ultimately aiming to become internationally influential pharmaceutical companies.
1. Global Pharmacies in Need of "Ammunition": Chinese Innovative Drugs as a Lifeline
Why have multinational companies suddenly turned their attention to Chinese innovative drugs? The root cause is the "patent cliff"—many of their best-selling drugs are nearing the end of their patent periods, and once the patents expire, generic versions will flood the market, causing a sharp drop in revenue. According to EY, by 2032, the world's top 25 pharmaceutical companies could lose $370 billion in earnings, leaving them with $2.1 trillion to invest in new projects to fill this gap.
Chinese innovative drugs meet this need perfectly. In the past, multinational companies were interested only in the Chinese market and its patient base; now, they are impressed by Chinese companies' achievements in cutting-edge areas like ADCs (precision cancer therapies that combine chemotherapy drugs with antibodies) and bispecific antibodies, which can target multiple targets. Some projects that take three years to complete abroad may be finished in China in just two years, providing much-needed time for these companies.
2. Chinese Innovative Drugs Going Global: From Being Ignored to Being Highly Desired
Just a few years ago, when Chinese pharmaceutical companies approached the U.S. for cooperation, they were often dismissed with vague responses; now, multinational companies are actively seeking information about the Chinese market. This shift is evident in licensing data: the proportion of Chinese innovative drug transactions in Europe and America increased from 8% in 2020 to 34% in 2025. In the first half of 2026, the amount of external licensing reached $99.7 billion, doubling the annual total for 2024.
For example, Haisco's projects have gained recognition; multinational companies now inquire in detail about the data and are willing to sign confidentiality agreements. This indicates that the technical prowess of Chinese innovative drugs is finally being recognized globally.
3. Hidden Concerns: Quick Money from "One-Way Sales," but Lack of Long-Term Value
Although licensing transactions seem promising, most Chinese companies still sell only early-stage projects, receiving upfront payments and milestone fees. However, the subsequent global sales profits, clinical development experience, and compliance capabilities remain with the foreign companies. For instance, if a Chinese company sells the global rights to a new drug for $1 billion in upfront and $2 billion in milestones, but the potential annual global sales are $5 billion, it only gets a portion of that amount and gains no knowledge about how to market the drug in Europe and America. This model may bring quick cash flow in the short term but limits the company's ability to develop its own global market.
4. Ways to Break the Pattern: More Than Just Selling Projects
Experts offer several practical suggestions:
- Strive for Co-Development Rights: Negotiate to include co-development, joint clinical trials, participation in key decision-making (e.g., choosing trial locations), and data sharing, while retaining sales rights in certain regions.
- Wait Until the Projects Are More Mature: If funding permits, wait until more substantial clinical data is available (e.g., successful phase II trials) before selling, which will increase your bargaining power.
- Create Competition: Negotiate with multiple companies to get better terms by encouraging competition among them.
- Build a Global Team: Hire professionals familiar with European and American clinical regulations and commercialization processes.
5. The Ultimate Goal: From Selling Technology to Building Global Giants
Zhu Xun from the Tongxiyi New Drug Talent Club emphasizes that while Chinese pharmaceuticals have made progress through imitation and project sales, they need to move beyond this. They should learn from industries like solar energy and high-speed rail, which developed from technology imports to independent innovation and eventually became global leaders. The future of Chinese innovative drugs lies in building their own global brands, capable of developing and selling drugs on a global scale, similar to companies like Pfizer and Merck. Only then can the Chinese pharmaceutical industry truly take its place at the international forefront.
This news highlights that Chinese innovative drugs have evolved from quantitative growth to qualitative improvement. To achieve greater success, they must shift from selling projects to building lasting capabilities and strategic partnerships.